Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial.
Maria F PatonJohn GierulaJudith E LowryDavid A CairnsKieran Bose RoslingCharlotte A ColeMelanie McGinlaySam StrawRowena ByromRichard M CubbonMark T KearneyKlaus K WittePublished in: PloS one (2021)
ClinicalTrials.gov identifier: NCT03627585.
Keyphrases
- phase ii
- clinical trial
- left ventricular
- open label
- study protocol
- multiple sclerosis
- double blind
- phase iii
- placebo controlled
- heart failure
- oxidative stress
- acute myocardial infarction
- hypertrophic cardiomyopathy
- aortic stenosis
- cardiac resynchronization therapy
- randomized controlled trial
- left atrial
- pulmonary embolism
- atrial fibrillation
- drug induced
- ejection fraction